HK Stock Market Move | PEGBIO CO-B(02565) increased more than 6% recently after receiving notice from cornerstone investors voluntarily extending lock-up period.
PAG Biopharma-B (02565) rose by over 6%, reaching 5.94% at the time of publication, with a price of 65.95 Hong Kong dollars and a trading volume of 5.0822 million Hong Kong dollars.
PEGBIO CO-B (02565) rose over 6%, as of the time of the press release, it has risen by 5.94%, to HK$65.95, with a turnover of HK$5.0822 million.
On the news front, PEGBIO CO-B announced that the final day of the original lock-up period (which was extended for the first time) is December 31, 2025. As of the date of this announcement, cornerstone investors collectively hold 9.5845 million H shares, accounting for approximately 3.43% of the total issued H shares of the company.
Recently, the company received a notice from the cornerstone investors, according to which, the cornerstone investors agreed not to reduce their holdings in any way from the original lock-up period (which was extended for the first time) until April 30, 2026. The company believes that the extension of the lock-up period for the second time indicates the cornerstone investors' confidence in the company's future prospects based on its ability to advance in technology research and achieve significant milestones in clinical development. The cornerstone investors will continue to review the company's performance and may consider further extensions of the lock-up period based on real-time developments and milestones achieved.
Related Articles

SPRING REIT (01426) spent 331,340 Hong Kong dollars to repurchase 200,000 fund units on December 24th.

Cathay Pacific Airways (00293) appoints Liu Tiexiang as non-executive director.

CITIC (00267): Zhang Lin resigns as non-executive director of the company
SPRING REIT (01426) spent 331,340 Hong Kong dollars to repurchase 200,000 fund units on December 24th.

Cathay Pacific Airways (00293) appoints Liu Tiexiang as non-executive director.

CITIC (00267): Zhang Lin resigns as non-executive director of the company

RECOMMEND





